Figure 2.
Relative change in VAFs of somatic mutations. (A-B) The change in VAFs of somatic mutations detected at diagnosis and after induction I and induction II in patients who were treated with LDC (A) or SDC (B). The thick black line shows the average VAF of all detected mutations; gray lines show the VAF of each single detected mutation. (C-D) Relative change in VAFs of the specific nonrandom AML-associated mutations at diagnosis and after induction I and induction II in the LDC (C) and SDC (D) groups. Nonrandom AML-associated genes were selected from the top 50 mutated AML-associated genes in pediatric AML and were detected recurrently in both groups. D0, at diagnosis; ID26, after induction I; IID26, after induction II; NA, not available.

Relative change in VAFs of somatic mutations. (A-B) The change in VAFs of somatic mutations detected at diagnosis and after induction I and induction II in patients who were treated with LDC (A) or SDC (B). The thick black line shows the average VAF of all detected mutations; gray lines show the VAF of each single detected mutation. (C-D) Relative change in VAFs of the specific nonrandom AML-associated mutations at diagnosis and after induction I and induction II in the LDC (C) and SDC (D) groups. Nonrandom AML-associated genes were selected from the top 50 mutated AML-associated genes in pediatric AML and were detected recurrently in both groups. D0, at diagnosis; ID26, after induction I; IID26, after induction II; NA, not available.

Close Modal

or Create an Account

Close Modal
Close Modal